title: The role of fulvestrant in endometrial cancer.
abstract: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Bogliolo
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Cassani
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Mattia
authors.initials: M
authors.lastname: Dominoni
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Orlandini
authors.affiliation: b Department of Obstetrics and Gynaecology , IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, University of Genoa , Genoa , Italy.
authors.forename: Simone
authors.initials: S
authors.lastname: Ferrero
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Anna Daniela
authors.initials: AD
authors.lastname: Iacobone
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Viazzo
authors.affiliation: b Department of Obstetrics and Gynaecology , IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, University of Genoa , Genoa , Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Venturini
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Arsenio
authors.initials: A
authors.lastname: Spinillo
authors.affiliation: a Department of Obstetrics and Gynaecology , IRCCS-Fondazione Policlinico San Matteo, University of Pavia , Pavia , Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Gardella
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D065171:Estrogen Receptor Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D011788:Quality of Life
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065171:Estrogen Receptor Antagonists; D000077267:Fulvestrant; D004958:Estradiol
keywords: Anti-hormone therapy; SERD; endometrial cancer; fulvestrant; gynecologic oncology; selective estrogen receptor down-regulators